Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 851-860 , November 2008

Comparison of semiquantitative fluorescence imaging and PET tracer uptake in mesothelioma models as a monitoring system for growth and therapeutic effects

  • Yuriko Saito

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, 263-8555, Japan
    • Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, Japan
    • ,
  • Takako Furukawa

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, 263-8555, Japan
    • Biomedical Imaging Research Center, University of Fukui, Yoshida, Fukui, 910-1193, Japan
    • Corresponding Author InformationCorresponding author.
    • ,
  • Yasushi Arano

      Affiliations

    • Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, 260-8675, Japan
    • ,
  • Yasuhisa Fujibayashi

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, 263-8555, Japan
    • Biomedical Imaging Research Center, University of Fukui, Yoshida, Fukui, 910-1193, Japan
    • ,
  • Tsuneo Saga

      Affiliations

    • Molecular Imaging Center, National Institute of Radiological Sciences, Chiba, 263-8555, Japan

Received 12 June 2008 ,Revised 10 August 2008 ,Accepted 26 August 2008.

References 

  1. Hazarika M, White RM, Booth BP, Wang YC, Ham DY, Liang CY, et al. Pemetrexed in malignant pleural mesothelioma. Clin Cancer Res. 2005;11:982–992
  2. Ramos-Nino ME, Testa JR, Altomare DA, Pass HI, Carbone M, Bocchetta M, et al. Cellular and molecular parameters of mesothelioma. J Cell Biochem. 2006;98:723–734
  3. Robledo R, Mossman B. Cellular and molecular mechanisms of asbestos-induced fibrosis. J Cell Physiol. 1999;180:158–166
  4. Kumar P, Kratzke RA. Molecular prognostic markers in malignant mesothelioma. Lung Cancer. 2005;49(Suppl 1):S53–S60
  5. McVeigh ER. Emerging imaging techniques. Circ Res. 2006;98:879–886
  6. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest. 2003;111:1620–1629
  7. Shaner NC, Campbell RE, Steinbach PA, Giepmans BN, Palmer AE, Tsien RY. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol. 2004;22:1567–1572
  8. Altomare DA, Vaslet CA, Skele KL, De Rienzo A, Devarajan K, Jhanwar SC, et al. A mouse model recapitulating molecular features of human mesothelioma. Cancer Res. 2005;65:8090–8095
  9. Craighead JE, Akley NJ, Gould LB, Libbus BL. Characteristics of tumors and tumor cells cultured from experimental asbestos-induced mesotheliomas in rats. Am J Pathol. 1987;129:448–462
  10. Robinson C, van Bruggen I, Segal A, Dunham M, Sherwood A, Koentgen F, et al. A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent. Cancer Res. 2006;66:10786–10794
  11. Kane AB. Animal models of malignant mesothelioma. Inhal Toxicol. 2006;18:1001–1004
  12. Deroose CM, De A, Loening AM, Chow PL, Ray P, Chatziioannou AF, et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med. 2007;48:295–303
  13. Kline RP, Wu EX, Petrylak DP, Szabolcs M, Alderson PO, Weisfeldt ML, et al. Rapid in vivo monitoring of chemotherapeutic response using weighted sodium magnetic resonance imaging. Clin Cancer Res. 2000;6:2146–2156
  14. Cullinane C, Dorow DS, Kansara M, Conus N, Binns D, Hicks RJ, et al. An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res. 2005;65:9633–9636
  15. Waldherr C, Mellinghoff IK, Tran C, Halpern BS, Rozengurt N, Safaei A, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F-fluorothymidine PET. J Nucl Med. 2005;46:114–120
  16. Kim TJ, Ravoori M, Landen CN, Kamat AA, Han LY, Lu C, et al. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma. Cancer Res. 2007;67:9337–9345
  17. Krohn KA, Mankoff DA, Muzi M, Link JM, Spence AM. True tracers: comparing FDG with glucose and FLT with thymidine. Nucl Med Biol. 2005;32:663–671
  18. Toyohara J, Waki A, Takamatsu S, Yonekura Y, Magata Y, Fujibayashi Y. Basis of FLT as a cell proliferation marker: comparative uptake studies with [3H]thymidine and [3H]arabinothymidine, and cell-analysis in 22 asynchronously growing tumor cell lines. Nucl Med Biol. 2002;29:281–287
  19. Dittmann H, Dohmen BM, Kehlbach R, Bartusek G, Pritzkow M, Sarbia M, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging. 2002;29:1462–1469
  20. Ramirez JM, Ocio EM, San Miguel JF, Pandiella A. Pemetrexed acts as an antimyeloma agent by provoking cell cycle blockade and apoptosis. Leukemia. 2007;21:797–804
  21. Kawai H, Toyohara J, Kado H, Nakagawa T, Takamatsu S, Furukawa T, et al. Acquisition of resistance to antitumor alkylating agent ACNU: a possible target of positron emission tomography monitoring. Nucl Med Biol. 2006;33:29–35
  22. Yau K, Price P, Pillai RG, Aboagye E. Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging. 2006;33:981–987
  23. Janne PA, Taffaro ML, Salgia R, Johnson BE. Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma. Cancer Res. 2002;62:5242–5247
  24. Vogelzang NJ, Porta C, Mutti L. New agents in the management of advanced mesothelioma. Semin Oncol. 2005;32:336–350
  25. Yang H, Bocchetta M, Kroczynska B, Elmishad AG, Chen Y, Liu Z, et al. TNF-alpha inhibits asbestos-induced cytotoxicity via a NF-kappaB-dependent pathway, a possible mechanism for asbestos-induced oncogenesis. Proc Natl Acad Sci U S A. 2006;103:10397–10402
  26. Molthoff CF, Klabbers BM, Berkhof J, Felten JT, van Gelder M, Windhorst AD, et al. Monitoring response to radiotherapy in human squamous cell cancer bearing nude mice: comparison of 2′-deoxy-2′-[18F]fluoro-D-glucose (FDG) and 3′-[18F]fluoro-3′-deoxythymidine (FLT). Mol Imaging Biol. 2007;9:340–347
  27. Buck AK, Kratochwil C, Glatting G, Juweid M, Bommer M, Tepsic D, et al. Early assessment of therapy response in malignant lymphoma with the thymidine analogue [18F]FLT. Eur J Nucl Med Mol Imaging. 2007;34:1775–1782
  28. Monazzam A, Josephsson R, Blomqvist C, Carlsson J, Langstrom B, Bergstrom M. Application of the multicellular tumours pheroid model to screen PET tracers for analysis of early response of chemotherapy in breast cancer. Breast Cancer Res. 2007;9:R45

PII: S0969-8051(08)00177-7

doi: 10.1016/j.nucmedbio.2008.08.002

Nuclear Medicine and Biology
Volume 35, Issue 8 , Pages 851-860 , November 2008

Article Tools

* Image Usage & Resolution